神经退行性疾病的药物输送是一个问题,但脂质纳米载体可以提供答案
1Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Nanotheranostics
|January 2, 2024
概括
脂质纳米粒子通过克服血脑屏障,为治疗神经退行性疾病提供了新的希望. 这些先进的药物载体在提供阿尔茨海默氏症等疾病治疗方法方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病涉及神经元退化,主要影响老年人群.
- 有效的治疗受到血脑屏障 (BBB) 的挑战,该屏障限制药物进入大脑.
- 像阿尔茨海默病,帕金森病和多发性硬化症这样的疾病是关键的研究领域.
研究的目的:
- 审查关于脂质纳米颗粒用于治疗神经退行性疾病的出版文献.
- 探索纳米颗粒在克服BBB的潜力,以增强药物输送到大脑.
主要方法:
- 专注于脂质纳米粒子和神经退行性疾病的科学文章的文献综述.
- 分析各种纳米载体系统及其在穿越血脑屏障方面的有效性.
主要成果:
- 基于脂质的纳米颗粒显示出作为治疗大脑疾病的有效药物输送系统的潜力.
- 几种类型的纳米粒子,包括脂质体和纳米乳液,被确定为有前途的候选物.
结论:
- 基于纳米粒子的药物输送为管理神经退行性疾病提供了一个可行的策略.
- 对脂质纳米颗粒的进一步研究可能会导致大脑疾病的治疗结果得到改善.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
127
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
127
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
Parkinson's Disease: Overview
553
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
553


